Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orchestra BioMed Holdings ( (OBIO) ) has issued an update.
On July 31, 2025, Orchestra BioMed Holdings announced securing $70 million in strategic capital from Ligand Pharmaceuticals and Medtronic to advance its late-stage cardiology programs. This investment includes Ligand’s $40 million commitment and Medtronic’s $30 million, reflecting confidence in Orchestra BioMed’s clinical progress and potential. The collaboration with Medtronic has been expanded to potentially integrate AVIM therapy into leadless pacemaker technology, aiming to transform care for patients with uncontrolled hypertension. This financial backing and strategic alignment are expected to support Orchestra BioMed in achieving key milestones in its high-impact clinical programs, addressing significant unmet medical needs in global markets.
The most recent analyst rating on (OBIO) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Orchestra BioMed Holdings stock, see the OBIO Stock Forecast page.
Spark’s Take on OBIO Stock
According to Spark, TipRanks’ AI Analyst, OBIO is a Neutral.
The overall stock score for Orchestra BioMed Holdings is 54, primarily influenced by significant financial performance challenges. While technical analysis provides a slightly positive outlook, and manageable debt levels offer some stability, the company’s negative profitability and cash flow issues are critical concerns. The valuation based on a negative P/E ratio and lack of dividends further reflects the risks associated with this investment.
To see Spark’s full report on OBIO stock, click here.
More about Orchestra BioMed Holdings
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company that accelerates high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Its business model focuses on strategic collaborations to drive global commercialization of its products. The company’s lead product candidate is AVIM therapy for hypertension, and it is also developing Virtue SAB for atherosclerotic artery disease. Orchestra BioMed has strategic collaborations with Medtronic and Terumo for the development and commercialization of these therapies.
Average Trading Volume: 251,227
Technical Sentiment Signal: Sell
Current Market Cap: $121.1M
See more data about OBIO stock on TipRanks’ Stock Analysis page.